Free
Meeting Abstracts  |   November 1999
Pancreatitis-associated Protein Protects the Lung from Leukocyte-induced Injury 
Author Affiliations & Notes
  • Axel Heller, M.D.
    *
  • Fritz Fiedler, M.D.
  • Joachim Schmeck, M.D.
  • Vanessa Lück, Cand.Med.
  • Juan L. Iovanna, M.D.
  • Thea Koch, M.D.
    *
  • *Professor of Anesthesiology, Department of Anesthesiology and Intensive Care Medicine, University Hospital Carl Gustav Carus, Dresden, Germany. †Professor of Anesthesiology, Department of Anesthesiology and Intensive Care Medicine, University Hospital Mannheim, Mannheim, Germany. ‡Professor of Anesthesiology, Institut National de la Santé et de la Recherche Médicale U315, Marseille, France.
Article Information
Meeting Abstracts   |   November 1999
Pancreatitis-associated Protein Protects the Lung from Leukocyte-induced Injury 
Anesthesiology 11 1999, Vol.91, 1408. doi:
Anesthesiology 11 1999, Vol.91, 1408. doi:
SEVERE pancreatitis is often complicated by acute lung failure, which increases mortality. 1 During severe pancreatitis, the cascade of inflammation is activated, resulting in the release of cytokines, e.g.  , tumor necrosis factor-α and interleukin-1 and -6 from macrophages and monocytes. 2,3 These early inflammatory cytokines have pleiotropic activity and act both locally and distally, causing the release of secondary wave cytokines, the expression of adhesion molecules, chemotaxis of leukocytes, and release of final mediators such as lipid mediators and reactive oxygen species. 4,5 The resulting increased capillary permeability is followed by edema formation. 6 
During pancreatitis, digestive enzymes such as amylase and lipase are downregulated, 7 and newly synthesized proteins are overexpressed. 8 In 1984, Keim et al.  9,10 identified a unique 16.6-kD secretory protein that was not detectable in the healthy gland but appeared 6 h after induction of experimental pancreatitis, reaching peak values after 48 h. 11 Therefore, the protein was called pancreatitis-associated protein (PAP). PAP may be of clinical relevance as a prognostic marker because a direct relationship between severity of pancreatitis and increased serum levels of PAP has been shown in rats 12 and humans. 11 Peak values ranged between 240 μg/l and 1,400 μg/l in patients with acute pancreatitis. 11,13 Little is known about the pathophysiologic impact of PAP. Recently, Fiedler et al.  14 demonstrated improved survival in animals with elevated levels of PAP in a rat model of necrotizing pancreatitis.
Pancreatitis-induced pulmonary distress has been implicated to be caused by cytokine-derived activation of leukocytes in the pulmonary vasculature. 15,16 Thus, effects of leukocyte activation in the lung are examined in the current study. To provoke respiratory burst, the well-established standardized method of receptor stimulation of leukocytes with N  -formyl-Met-Leu-Phe (fMLP) was used. 17 
The aim of the current study was to evaluate the effect of PAP in leukocyte-associated lung failure. The effects of PAP on pulmonary vascular resistance and edema formation were investigated, and synthesis of thromboxane (TX) A2was measured by analyzing its stable metabolite, TXB2.
Materials and Methods 
Isolated Rabbit Lung 
The techniques of preparing and perfusing isolated rabbit lungs have been previously described in detail. 18,19 After approval by the local board for animal protection, female chinchilla rabbits (Orticolagus caniculus  ) weighing 2,100 ± 196 g (mean ± SD) were anesthetized with ketamine (50 mg/kg) and xylazine (4 mg/kg) and anticoagulated with heparin–sodium 1,000 U/kg injected in the ear vein. After placement of a tracheostomy tube, the rabbits were mechanically ventilated with room air. The thorax was opened via  the diaphragm, and after a median sternotomy, a catheter was inserted into the pulmonary artery. The lung organ preparation was isolated and suspended from a weight transducer in a temperature-controlled (37°C) and humidified chamber. After the cannulation procedure, the lungs were perfused with 200 ml Krebs Henseleit hydroxy-ethyl-starch buffer solution (KHB) by a roller pump at a constant volume inflow of 150 ml/min in a closed recirculatory system with an open reservoir to collect outflow from the left atrium. Pulmonary embolism by circulating particles or air was prevented by a 40-μm filter and a bubbletrap placed right before the pulmonary artery catheter. The lungs were ventilated with 4% CO2in air (frequency, 25 breaths/min; tidal volume, 30 ml; positive end-expiratory pressure, 0.5–1.0 cm H2O) and, to avoid atelectasis formation, intermittently expanded by increasing the expiratory pressure up to 3 cm H2O for three inspirations. The mean pulmonary arterial pressure (mpap) and airway pressures were continuously recorded via  Statham strain-gauge transducers. Because oxygenation of the lung by ventilation was satisfactory and previous experiments did not show any hypoxic cellular damage, 20 no additional oxygenator unit in the perfusion circuit was required. Because of a constant perfusion flow, alterations of perfusion pressure directly reflect alterations of pulmonary vascular resistance. Samples of perfusate were taken intermittently from a catheter that collects the effluent from the pulmonary veins, for measurements of p  H, oxygen and carbon dioxide partial pressure, oxygen saturation (blood gas analysis system 288; Ciba Corning, Fernwald, Germany), oncotic pressure (Onkometer BMT 921, Dr. Karl Thomae GmbH, Berlin, Germany), and determination of TXB2concentrations. The lungs were initially perfused with KHB solution using low flow rates in an open circulatory system to remove remaining blood from the vascular bed. The perfusion fluid was then exchanged for fresh buffer via  two separate perfusion circuits 2 min after the beginning of the extracorporeal circulation and 15 min later, after the flow was increased to 150 ml/min. After another 30-min steady-state period, these lungs had a constant mean mpap of 8–9 mmHg (zero-referenced at the hilum). The only lungs selected for the study were those that showed a homogenous white appearance with no signs of hemostasis or edema formation and that had no changes in weight during the steady-state period. In previous experiments, perfusion with KHB has been documented to maintain integrity of the microcirculation for more than 5 h in our model, which was assessed by measurements of mpap and weight gain, by biochemical analysis (lactate dehydrogenase, arachidonic acid metabolites, histamine), and by ultrastructural studies. 20 
Preparation and Purification of Rat PAP 
Male Sprague Dawley rats (250–300 g) were housed with free access to food and water. The main pancreatic duct was cannulated under ether anesthesia, and edematous pancreatitis was induced by intravenous infusion of cerulein (5 μg · kg−1· h−1) for 6 h. 21 Pancreatic juice was collected on ice for several hours as previously described 22 and immediately frozen, lyophilized, and stored at −70°C.
Affinity Chromatography 
A specific antirat-PAP antibody 23 was prepared according to the method described by Iovanna et al.  24 and was covalently bound to a solid matrix (Affi-Gel 10 gel; Bio-Rad, Ivry sur Seine, France) according to the manufacturers’ specifications. The column was equilibrated with 2-[N  -morpholino] ethane sulfonic acid buffer (20 mM;p  H 6.5) with 150 mM NaCl. Lyophilized pancreatic juice was resuspended in 2-[N  -morpholino] ethane sulfonic acid buffer (20 mM;p  H 6.5), 150 mM NaCl, 5 mM benzamidine, 2 mM phenylmethylsulfonyl fluoride, and 5 mM N  α-benzoyl-L-arginin. After centrifugation (3,000 g  for 15 min), the supernatant was applied to the affinity gel column and recirculated overnight at 4°C. Thereafter, the column was washed with 2-[N  -morpholino] ethane sulfonic acid buffer to elute unbound contaminants. The bound protein was eluted with glycine buffer (200 mM;p  H 2.8), dialyzed against phosphate-buffered saline buffer, and concentrated by centrifugation with Centrifugal Ultrafree-20-Kit (Millipore; Saint-Quentin, France).
Quality Control of Protein Isolation 
Protein concentration was measured according to Bradford. 25 Part of the protein solution was submitted to sodium dodecyl sulfate–polyacrylamide gel electrophoresis (15% acrylamide; 0.5% bisacrylamide), which was performed according to standard procedures. 26 The gels were either stained by a silver-staining method, 27 or the samples were blotted on nitrocellulose membranes, and Western blot analysis was performed with a specific antirat-PAP antibody. 23,24,26 Silver staining revealed a single protein band corresponding to the molecular weight of PAP, which crossreacts with the antirat-PAP antibody during Western blot analysis, indicating that the purified protein was indeed PAP.
Experimental Protocol 
Thirty lung preparations were randomly assigned to the different groups. After a 30-min equilibration period, the first perfusate sample was drawn for measurements of baseline values. In pilot experiments, the effects of different concentrations of PAP (260 μg/l, n = 3; 500 μg/l, n = 3; 1,000 μg/l, n = 3) were investigated. Therefore, only PAP was administered after the steady-state phase, and mpap and weight gain of the lungs were monitored for 150 min. Samples of perfusate were taken at 5, 10, 30, 60, 120, 150 min to investigate TXB2release and to analyze blood gases.
As in pancreatitis-induced lung injury, which is likely to be leukocyte-mediated via  inflammatory receptor stimulation, neutrophil activation was achieved in six lung preparations without further interventions. For this purpose, the chemotactic peptide fMLP was added after a 30-min steady-state period, yielding a final concentration of 10−6M in the perfusion fluid, and monitoring was performed as described for the pilot experiments (control group). To study protective effects of PAP on polymorphonuclear neutrophil leukocyte–mediated lung injury, in the experimental groups PAP was added to the perfusion fluid in two different concentrations (260 μg/l, n = 9; or 500 μg/l, n = 6) 15 min before fMLP administration (10−6M). These concentrations have been reported in moderate to severe pancreatitis. 11 The applied time schedule was chosen to guarantee a uniform distribution of PAP in the whole lung before inflammatory activation, which induces transient perfusion inhomogenities. Monitoring of mpap, weight gain, TXB2, and blood gases was performed similar to the other groups.
Measurement of TXB2 
Thromboxane B2was assayed from 100 μl of recirculating KHB as stable hydrolysis product of TXA2by an enzyme immunoassay (TiterZyme TXB2EIA; PerSeptive Diagnostics Inc., Framingham, MA). The immunoassay and the photometric measurement (AR 2001 photometer; Anthos Labtech Instruments, Krefeld, Germany) were performed according to the manufacturers specifications. The crossreactivity of TXB2-antiserum with 2,3-Dinor-TXB2was 55.8%, 1.5% with 11-Dehydro TXB2, 1.0% with prostaglandin B2, and 0.5% with prostaglandin D2. Other eicosanoids exert cross reactivity less than 0.1%.
Because the lungs in the current study were perfused in a closed circuit, the inactive metabolite TXB2accumulated over the observation period in the perfusate. Thus, TXB2release was calculated per minute as the difference of TXB2to the previous value divided by the time in minutes.
Materials 
A cell- and plasma-free perfusion medium was used to avoid the complex interactions with different circulating cells, which may mask direct effects on vascular tone and mediator release. The perfusate consisted of a Krebs-Henseleit buffer solution with a colloid oncotic pressure between 23 and 25 mmHg, yielding the following final concentrations: Na+, 138 mM; K+, 4.5 mM; Mg++, 1.33 mM; Cl, 135 mM; Ca++, 2.38 mM; glucose, 12 mM; HCO3, 12 mM. The osmolality was approximately 330 mOsm/kg (Mikro-Osmometer; Roebling Meßtechnik, Berlin, Germany). The p  H of the buffer solution was adjusted to 7.4 with 1 M NaHCO3. Effects caused by endotoxin contamination of the plasma-free perfusate can be excluded in our model, as assessed in previous experiments. 28 No hemodynamic reactions, thromboxane generation, or histamine release was observed after endotoxin addition to the perfusate in the absence of plasma complement components. 28 
fMLP 
N  -formyl-Met-Leu-Phe was purchased from Sigma Chemicals (Deisenhofen, Germany), dissolved in dimethyl sulfoxide, and stored deep-frozen until use. Final concentrations of fMLP in the pulmonary circuit were 10−6M.
Statistical Analysis and Data Presentation 
Data are presented as mean ± SD. Differences between groups were tested by one-way analysis of variance followed by a Student Newman-Keuls multiple-comparison procedure. Significance was accepted at P  < 0.05.
This study was approved by the Animal Subject Protection Committee of the local government. The care and handling of animals were in accordance with the principles expressed in the Helsinki Declaration.
Results 
After an equilibration period of 30 min, baseline values of mpap (8 ± 2 mmHg) and airway pressure (6–8 cm H2O) were similar in all groups and in agreement with previous studies reported by our group. 18 Because effects of PAP on the pulmonary vasculature are unknown, administration of PAP was investigated to determine its properties in our lung preparation. During perfusion with any concentration of PAP (260 μg/l, n = 3; 500 μg/l, n = 3; 1,000 μg/l, n = 3), no changes in mpap, weight gain, or TXB2release were observed, and the lung preparations were stable until the end of the 150-min observation period. The leukocyte activation with fMLP in the lungs resulted in an acute increase of mpap up to 26 ± 13 mmHg (P  < 0.01) within 5 min (fig. 1). Baseline levels of mpap were regained 30 min after fMLP addition and were then maintained for 120 min. A dose-dependent effect on mpap was observed after treatment with PAP. The pressure response was reduced significantly to 15 ± 7 mmHg (PAP 260 μg/l;P  < 0.05) and 9 ± 4 mmHg (PAP 500 μg/l), respectively. Mean pulmonary artery pressure returned to baseline 10 min after fMLP and remained almost constant until the end of the experiment. fMLP induced lung weight gain of 9 ± 7 g during the 150-min observation period, whereas pretreatment with PAP in either concentration significantly (P  < 0.05) prevented pulmonary edema formation (PAP 260 μg/l, 2 ± 2 g; 500 μg/l, 1 ± 2 g;fig. 2).
Fig. 1. Mean pulmonary artery pressure (mpap;± SD) of lungs in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of different concentrations of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, analysis of variance. PAP reduced mpap in a dose-dependent manner. Baseline values before fMLP administration at time point 0. 
Fig. 1. Mean pulmonary artery pressure (mpap;± SD) of lungs in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of different concentrations of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, analysis of variance. PAP reduced mpap in a dose-dependent manner. Baseline values before fMLP administration at time point 0. 
Fig. 1. Mean pulmonary artery pressure (mpap;± SD) of lungs in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of different concentrations of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, analysis of variance. PAP reduced mpap in a dose-dependent manner. Baseline values before fMLP administration at time point 0. 
×
Fig. 2. Weight gain of lungs (± SD) in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, analysis of variance. PAP reduced weight gain in a dose-dependent manner. 
Fig. 2. Weight gain of lungs (± SD) in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, analysis of variance. PAP reduced weight gain in a dose-dependent manner. 
Fig. 2. Weight gain of lungs (± SD) in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, analysis of variance. PAP reduced weight gain in a dose-dependent manner. 
×
Analysis of perfusate samples revealed a baseline concentration of circulating TXB2of 2.63 ± 2.60 nmol/ml and an immediate increase (P  < 0.005) after fMLP injection. PAP significantly suppressed TXB2formation caused by fMLP injection compared with controls. Although mean values in controls reached 1,138 ± 800 pmol · ml−1· min−1, TXB2detected in the PAP groups were 200 ± 220 pmol · ml−1· min−1(P  < 0.01; PAP 260 μg/l) and 285 ± 70 pmol · ml−1· min−1(P  < 0.05; PAP 500 μg/l) 5 min after fMLP injection (fig. 3).
Fig. 3. Release of thromboxane (TX) B2(± SD), a stable metabolite of TXA2, into the perfusate of isolated rabbit lungs in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, **  P  < 0.01  vs.  fMLP, analysis of variance. PAP reduced TXB2generation in a dose-dependent manner. 
Fig. 3. Release of thromboxane (TX) B2(± SD), a stable metabolite of TXA2, into the perfusate of isolated rabbit lungs in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, **  P  < 0.01  vs.  fMLP, analysis of variance. PAP reduced TXB2generation in a dose-dependent manner. 
Fig. 3. Release of thromboxane (TX) B2(± SD), a stable metabolite of TXA2, into the perfusate of isolated rabbit lungs in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, **  P  < 0.01  vs.  fMLP, analysis of variance. PAP reduced TXB2generation in a dose-dependent manner. 
×
Oxygen saturation, oxygen and carbon dioxide partial pressures, and p  H and base excess did not significantly change throughout the observation period in all experiments.
Discussion 
Pulmonary dysfunction such as pulmonary edema and hypoxemia is one of the main systemic complications in acute pancreatitis. 1,6 Experimental studies provided evidence that pancreatitis induces cytokines that activate granulocytes in the lung vasculature, initiating pulmonary damage 15 by elastase and phospholipase A2release. 29 Despite intensive research efforts, until now the effects of potential modifiers of this inflammatory response, such as heat shock proteins and PAP, are not well understood. Recently, characteristic alterations of protein synthesis at translational and transcriptional levels were detected during acute pancreatitis. 8 The most prominent finding was the overexpression of an unique c-lectin protein in the pancreas of animals 9 and humans. 10 This protein is absent in the normal gland but synthesized in high amounts in the inflamed pancreas. 12 During inflammation, evidence accumulated that the acute-phase protein response, including PAP, exerts beneficial effects in different species and in distinct experimental settings. 14 After induction of acute pancreatitis in rats, PAP was first detected after 6 h. Maximum levels corresponding to a 400–1,000-fold increase of PAP were measured within 48 h. 11,30 Considering that high amounts of this unique protein are expressed during acute pancreatitis correlating with the severity of disease, 11 but also correlating with increased survival in rats, 14 our interest was focused on whether PAP might show organ protective properties in a model of pancreatitis-associated lung failure. Because alterations in vascular tone and a capillary leak are hallmarks of acute respiratory distress syndrome, the study was designed to investigate the pathophysiologic effects of this protein on fMLP-induced leukocyte activation and on subsequent pulmonary vascular resistance and edema formation. For this purpose, highly purified PAP from rat pancreatic juice was added to the perfusion fluid of the isolated lung. The applied dosage in our model was comparable to serum levels measured in patients with mild to severe pancreatitis. 11 To guarantee homologous distribution of PAP in the lung, PAP was administered before the inflammatory fMLP stimulus.
Although the isolated-cell free perfused rabbit lung is a relatively simple model that allows the investigation of PAP effects under standardized conditions, there are particular limitations. It does not allow analysis of interactions with other organ systems or between the endothelium and blood components. Moreover, the observation period is limited to approximately 6 h. However, this experimental set-up allows selective measurements of alterations in pulmonary vascular resistance and permeability as well as the release of mediators into the perfusate. Therefore, conclusions on pathophysiologic mechanisms can be drawn from this model. 18–20 It has been shown that granulocyte activation by proinflammatory cytokines plays a crucial role in pulmonary damage during pancreatitis. 4,5 Thus, activation of granulocytes by fMLP in the lung vasculature was chosen in the present study. Although fMLP-induced lung injury may reproduce some features of injury produced by pancreatitis, inflammation in vivo  is considerably more complex, characterized by a mounting cascade of a variety of mediators released from a variety of inflammatory cells. These additional factors may modulate the actual effect of PAP during clinical pancreatitis. The time course of pulmonary artery pressure, with maximum vasoconstriction after 5 min and decreasing values until baseline at 30 min, is in agreement with that of other investigators 31 using fMLP in isolated lungs.
The current data on PAP-induced effects on lung vascular tone and edema formation demonstrate protective properties of PAP on leukocyte-induced pulmonary injury. Pulmonary artery pressure (fig. 1) as well as edema formation (fig. 2) in the lung were significantly suppressed after pretreatment with PAP, whereas application of PAP without leukocyte activation did not affect any measured parameter. In seeking to understand the protective effects of PAP concerning the acute pressure increase after polymorphonuclear neutrophil leukocyte activation, the role of TXA2as a potent vasoconstrictive mediator in the pulmonary circulation 32,33 was investigated in the presence and absence of PAP. The generation and release of this mediator is induced by a variety of factors, including tissue damage, allergic reaction, infection, and other inflammatory diseases. TXA2is supposed to be the predominant mediator of arachidonic acid–induced pressure responses in rabbit lungs, surpassing the vasodilatory properties of simultaneously generated prostacyclin. This was confirmed in our model in previous studies. 34 In the current study, the release of TXA2into the perfusate corresponded with an increase in pulmonary artery pressure in all experimental set-ups. Hence, PAP dose-dependently suppressed TXA2generation, which was associated with the modulation of the pulmonary pressure response (fig. 3).
In the present study, PAP was obtained from rats by affinity chromatography, which is highly selective for PAP, and its purity was checked carefully, 23,25–27 indicating that the isolated protein indeed was PAP. Thus, effects caused by impurities can be excluded, and the present data precisely reflects properties of PAP. Homology of human and rat PAP has been described 35 in terms of size, 71% amino acid identity, and the six half-cystines being in identical positions. Because rabbit PAP has not been sequenced, assumptions about the structure of rabbit PAP remain speculative. Nevertheless, the data obtained in this xeno-model indicate protective effects of the investigated protein without any signs of foreign protein reaction, which would evoke alterations in vascular tone and permeability in isolated lungs. 36 Because PAP has been described as a nonenzymatic protein without protease activity, its effects on fMLP-induced pulmonary damage are very unlikely to be caused by hydrolysis of fMLP, which would cause insufficient leukocyte activation. The distinct molecular mechanisms of action cannot be answered from the current study design.
Antiapoptotic properties of PAP have been reported 37 that protect AR4–2J cells from oxygen radical–induced cell injury. Although reactive oxygen species play a crucial role in pancreatitis-induced pulmonary damage and were released in our model after fMLP stimulation, protection from apoptosis might contribute to the observed effects. Whether the observed protective effects of PAP on acute lung injury play a significant role in human acute respiratory distress syndrome after acute pancreatitis remains to be elucidated.
In summary, PAP prevents polymorphonuclear neutrophil leukocyte–mediated pulmonary vasoconstriction and edema formation in the isolated rabbit lung in concentrations found during pancreatitis. These findings point toward a protective effect of PAP on pancreatitis-associated lung injury.
The authors thank K. Salomon, J. Schulte, and A. Tapper (Institute of Anesthesiology, University Hospital Mannheim, Mannheim, Germany); J. Christophel (Center of Medical Research, University Hospital of Mannheim, Mannheim, Germany); and M. A. Devaux (INSERM U315, Marseille, France) for excellent technical assistance.
References 
References 
Ranson JH, Roses DF, Fink SD: Early respiratory insufficiency in acute pancreatitis. Ann Surg 1973; 178:75–9
Norman J: The role of cytokines in the pathogenesis of acute pancreatitis. Am J Surg 1998; 175:76–83
Denham W, Yang J, Norman J: Evidence for an unknown component of pancreatic ascites that induces adult respiratory distress syndrome through an interleukin-1 and tumor necrosis factor-dependent mechanism. Surgery 1997; 122:295–301
Baumann H, Gauldie J: The acute phase response. Immunol Today 1994; 15:74–80
Murakami H, Nakao A, Kishimoto W, Nakano M, Takagi H: Detection of O2-generation and neutrophil accumulation in rat lungs after acute necrotizing pancreatitis. Surgery 1995; 118:547–54
Temmesfeld-Wollbruck B, Walmrath D, Grimminger F, Seeger W: Prevention and therapy of the adult respiratory distress syndrome. Lung 1995; 173:139–64
Iovanna JL, Keim V, Michel R, Dagorn JC: Pancreatic gene expression is altered during acute experimental pancreatitis in the rat. Am J Physiol 1991; 261:485–9
Keim V, Iovanna JL, Dagorn JC: The acute phase reaction of the exocrine pancreas: Gene expression and synthesis of pancreatitis-associated proteins. Digestion 1994; 55:65–72
Keim V, Rohr G, Stockert HG, Haberich FJ: An additional secretory protein in the rat pancreas. Digestion 1984; 29:242–9
Keim V, Iovanna JL, Orelle B, Verdier JM, Busing M, Hopt U, Dagorn JC: A novel exocrine protein associated with pancreas transplantation in human. Gastroenterology 1992; 103:248–54
Iovanna JL, Keim V, Nordback I, Montalto G, Camarena J, Letoublon C, Levy P, Berthezene P, Dagorn JC: Serum levels of pancreatits-associated protein as indicators of the course of acute pancreatitis. Gastroenterology 1994; 106:728–34
Iovanna J, Orelle B, Keim V, Dagorn JC: Messenger RNA sequence and expression of rat pancreatitis-associated protein, a lectin-related protein overexpressed during acute experimental pancreatitis. J Biol Chem 1991; 266:24664–9
Keim V, Willemer S, Iovanna JL, Adler G, Dagorn JC: Rat pancreatitis-associated protein is expressed in relation to severity of experimental pancreatitis. Pancreas 1994; 9:606–12
Fiedler F, Croissant N, Rehbein C, Iovanna JL, Dagorn JC, van Ackern K, Keim V: Acute-phase response of the rat pancreas protects against further aggression with severe necrotizing pancreatitis. Crit Care Med 1998; 26:887–94
O'Donovan DA, Kelly CJ, Bouchier-Hayes DM, Grace P, Redmond HP, Burke PE, Bouchier-Hayes EJ: Alpha-1-antichymotrypsin is an effective inhibitor of pancreatitis-induced lung injury. Eur J Gastroenterol Hepatol 1995; 7:847–52
Donnelly SC, Strieter RM, Kunkel SL, Walz A, Robertson CR, Carter DC, Grant IS, Pollok AJ, Haslett C: Interleukin-8 and development of adult respiratory distress syndrome in at-risk patient groups. Lancet 1993; 341:643–7
Yamazaki M, Matsuoka T, Yasui K, Komiyama A, Akabane T: Increased production of superoxide anion by neonatal polymorphonuclear leukocytes stimulated with a chemotactic peptide. Am J Hematol 1988; 27:169–73
Heller A, Ragaller M, Schmeck J, Fluth H, Muller M, Albrecht DM, Koch T: Role of NO and endothelin in hemoglobin-induced pulmonary vasoconstriction. Shock 1998; 10:401–6
Seeger W, Walmrath D, Grimminger F, Rosseau S, Schutte H, Kramer H-J, Ermert L, Kiss L: Adult respiratory distress syndrome: Model systems using isolated perfused rabbit lungs. Methods Enzymol 1994; 233:549–84
Koch T, Duncker HP, Rosenkranz S, Neuhof H, van Ackern K: Alterations of filtration coefficients in pulmonary edema of different pathogenesis. J Appl Physiol 1992; 73:2396–402
Adler G, Rohr G, Kern HF: Alteration of membrane fusion as a cause of acute pancreatitis in the rat. Dig Dis Sci 1982; 27:993–1002
Keim V, Goke B, Adler G: Changes in pattern of enzyme secretion by rat pancreas during repeated trypsin inhibitor treatment. Am J Physiol 1988; 255:36–41
Keim V, Iovanna JL, Rohr G, Usadel KH, Dagorn JC: Characterization of a rat pancreatic secretory protein associated with pancreatitis. Gastroenterology 1991; 100:775–82
Iovanna JL, Keim V, Bosshard A, Orelle B, Frigerio JM, Dusetti N, Dagorn JC: PAP, a pancreatic secretory protein induced during acute pancreatitis, is expressed in rat intestine. Am J Physiol 1993; 265:11–8
Bradford MM: A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72:248–54
Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY, Cold Spring Harbor Laboratory, 1989
Heukeshoven J, Dernick R: Silberfärbung von Proteinen in SDS-Gelen, Elektrophorese Forum. Edited by Radola BJ. Berlin, Springer, 1983, pp 92–7
Koch T, Neuhof H, Duncker HP, Stein A, Moschet B, Schonharting M, van Ackern K: Influence of a pentoxifylline-analogue on the granulocyte mediated pulmonary mediator release and vascular reaction. Circ Shock 1993; 40:83–91
Hirano T, Manabe T: A new synthetic elastase inhibitor, EI-546, protects lungs but not pancreas in caerulein-induced pancreatitis in the rat. Med Sci Res 1992; 20:473–4
Dusetti NJ, Frigerio JM, Keim V, Dagorn JC, Iovanna JL: Structural organization of the gene encoding the rat pancreatitis-associated protein: Analysis of its evolutionary history reveals an ancient divergence from the other carbohydrate-recognition domain-containing genes. J Biol Chem 1993; 268:14470–5
Tanaka H, Bradley JD, Baudendistel LJ, Dahms TE: Mechanisms of pulmonary vasoconstriction induced by chemotactic peptide FMLP in isolated rabbit lungs. J Appl Physiol 1992; 72:1549–56
Hamasaki Y, Mojarad M, Saga T, Tai HH, Said SI: Platelet-activating factor raises airway and vascular pressures and induces edema in lungs perfused with platelet-free solution. Am Rev Respir Dis 1984; 129:742–6
Heller A, Koch T, Schmeck J, van Ackern K: Lipid mediators in inflammatory disorders. Drugs 1998; 55:487–96
Seeger W, Ernst C, Walmrath D, Neuhof H, Roka L: Influence of the thromboxane antagonist BM 13.177 on the arachidonic acid-induced increase in pulmonary vascular resistance and permeability in rabbit lungs. Thromb Res 1985; 40:793–805
Orelle B, Keim V, Masciotra L, Dagorn JC, Iovanna JL: Human pancreatitis-associated protein: Messenger RNA cloning and expression in pancreatic diseases. J Clin Invest 1992; 90:2284–91
Heller A, Kirschfink M: Effects of C1-inhibitor and sCR-1 on complement induced lung injury (abstract). Acta Anaesthesiol Scand 1997; 41(Suppl):100
Ortiz EM, Dusetti NJ, Vasseur S, Malka D, Bodeker H, Dagorn JC, Iovanna JL: The pancreatitis-associated protein is induced by free radicals in AR4–2J cells and confers cell resistance to apoptosis. Gastroenterology 1998; 114:808–16
Fig. 1. Mean pulmonary artery pressure (mpap;± SD) of lungs in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of different concentrations of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, analysis of variance. PAP reduced mpap in a dose-dependent manner. Baseline values before fMLP administration at time point 0. 
Fig. 1. Mean pulmonary artery pressure (mpap;± SD) of lungs in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of different concentrations of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, analysis of variance. PAP reduced mpap in a dose-dependent manner. Baseline values before fMLP administration at time point 0. 
Fig. 1. Mean pulmonary artery pressure (mpap;± SD) of lungs in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of different concentrations of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, analysis of variance. PAP reduced mpap in a dose-dependent manner. Baseline values before fMLP administration at time point 0. 
×
Fig. 2. Weight gain of lungs (± SD) in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, analysis of variance. PAP reduced weight gain in a dose-dependent manner. 
Fig. 2. Weight gain of lungs (± SD) in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, analysis of variance. PAP reduced weight gain in a dose-dependent manner. 
Fig. 2. Weight gain of lungs (± SD) in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, analysis of variance. PAP reduced weight gain in a dose-dependent manner. 
×
Fig. 3. Release of thromboxane (TX) B2(± SD), a stable metabolite of TXA2, into the perfusate of isolated rabbit lungs in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, **  P  < 0.01  vs.  fMLP, analysis of variance. PAP reduced TXB2generation in a dose-dependent manner. 
Fig. 3. Release of thromboxane (TX) B2(± SD), a stable metabolite of TXA2, into the perfusate of isolated rabbit lungs in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, **  P  < 0.01  vs.  fMLP, analysis of variance. PAP reduced TXB2generation in a dose-dependent manner. 
Fig. 3. Release of thromboxane (TX) B2(± SD), a stable metabolite of TXA2, into the perfusate of isolated rabbit lungs in which leukocyte activation was performed with 10−6M  N  -formyl-Met-Leu-Phe (fMLP) in the absence or in presence of pancreatitis-associated protein (PAP; 260 μg/l, n = 9; 500 μg/l, n = 6). *  P  < 0.05  vs.  fMLP, **  P  < 0.01  vs.  fMLP, analysis of variance. PAP reduced TXB2generation in a dose-dependent manner. 
×